Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Explore linked clinical trials.294 results · Page 1 of 12
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Study of Three-dimensional Lattice Radiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Advanced Solid Tumors | Advanced Malignant Solid Tumor | Recruiting | Phase 2 | 2026-10-08 | NCT07865793 | |
| SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC | Brain Metastases, Neoplasms by Site, Thoracic Neoplasms, brain disorder, bronchial neoplasm, bronchogenic carcinoma, central nervous system cancer, central nervous system disorder, lung disorder, lung neoplasm, neoplasm, nervous system disorder, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 3 | 2026-10-08 | NCT06457906 | |
| The QL1706 Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentially Resectable Colorectal Cancer Patients With Liver Metastases | Colorectal Cancer Metastatic to Liver | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-07 | NCT07863869 | |
| Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma | Aggressive Lymphoma | Recruiting | Not applicable | 2026-10-07 | NCT07657494 | |
| Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma | Concurrent Chemoradiotherapy; Immunonutrition; Locally Advanced Esophageal Squamous Cell Carcinoma; Radiotherapy; Sintilimab | Recruiting | Phase 2 | 2026-10-07 | NCT06342167 | |
| Phase I Study of In Vivo CAR-Tumor Technology for the Treatment of Advanced Malignant Tumors | Advanced Solid Tumor | Not yet recruiting | Phase 1 | 2026-10-05 | NCT07859462 | |
| Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Recruiting | Not stated | 2026-10-05 | NCT07858630 | |
| Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance | EGFR-TKI-resistant Non-Small Cell Lung Cancer | Not yet recruiting | Phase 1 | 2026-09-25 | NCT07842887 | |
| Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy | Advanced Urothelial Carcinoma | Recruiting | Phase 1 | 2026-09-22 | NCT07835035 | |
| Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer | Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | Active, not recruiting | Not stated | 2026-09-22 | NCT07429318 | |
| Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, cervical squamous cell carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell lung carcinoma, squamous cell neoplasm | Active, not recruiting | Not stated | 2026-09-18 | NCT07147361 | |
| Video-Assisted Thoracoscopic Surgery Combined With Radiofrequency Ablation Versus VATS Alone for Multiple Primary Lung Cancer | Multiple Primary Lung Cancers | Not yet recruiting | Not applicable | 2026-09-15 | NCT07819669 | |
| Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal cancer, rectal disorder, rectal neoplasm | Recruiting | Not applicable | 2026-09-15 | NCT06146946 | |
| A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma | Advanced HBV-Related Hepatocellular Carcinoma | Recruiting | Phase 1 | 2026-08-31 | NCT07557251 | |
| ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC | Neoplasm, Residual, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Active, not recruiting | Not stated | 2026-08-31 | NCT05198154 | |
| YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC) | DNA Virus Infections, Infections, Neoplasms by Site, Thoracic Neoplasms, adenoviridae infectious disease, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, viral infectious disease | Recruiting | Early phase 1 | 2026-08-28 | NCT07793500 | |
| A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma | Hemic and Lymphatic Diseases, Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 2 | 2026-08-28 | NCT07791615 | |
| Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 2 | 2026-08-28 | NCT07791602 | |
| Establishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study | Meta-Learning; Multimodal; Predictive Models; Triple -Negative Breast Cancertriple | Recruiting | Not stated | 2026-08-19 | NCT07773818 | |
| Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer | Disease Attributes, Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, neoplasm | Recruiting | Not stated | 2026-08-18 | NCT06993506 | |
| Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer(UPGRADE-TNBC) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Enrolling by invitation | Phase 2 / Phase 3 | 2026-08-18 | NCT06910072 | |
| COLORS-Validate Study of Decision-Support Software for Surgical Sequencing in Colorectal Liver Metastases | Colorectal Liver Metastases | Not yet recruiting | Not stated | 2026-08-12 | NCT07760558 | |
| SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Not yet recruiting | Phase 2 | 2026-08-06 | NCT07749859 | |
| Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Cervical Cancer | Cancer of the Uterine Cervix, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Not applicable | 2026-08-05 | NCT07684508 | |
| MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Not yet recruiting | Phase 2 | 2026-08-05 | NCT07677475 |